Jing Li

Jing Li has a strong work experience in the pharmaceutical industry. Starting in 2002, Jing Li worked as a Research Scientist at Cumbre Pharmaceuticals Inc. where they made significant contributions to several antibacterial programs and completed Phase I clinical trial for the novel antibacterial agent CBR-2092. In 2005, Jing Li joined Millennium Pharmaceuticals as a Scientist I and II before moving to Cubist Pharmaceuticals in 2007 as a Sr Scientist/Team Leader. In 2008, Jing Li joined Merck as an Associate Principal Scientist, where they worked until 2016. At Merck, they held the role of President of PharmaBlock USA and SVP of Process Chemistry at PharmaBlock Sciences from October 2016 onwards.

Jing Li completed a postdoc in Chemistry at UT Southwestern Medical Center from 1999-2002. Prior to that, they earned a Ph.D. in Chemistry from Nanjing University, graduating in 1998. In addition, they obtained a certification in Executive Development Program from Wharton Executive Education in the year 2020.